Your gift is 100% tax deductible
LIMITED TIME OFFER! Give now and have your gift 3X matched, up to $75,000. Donate Now.
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
After someone is diagnosed with non-Hodgkin lymphoma (NHL), doctors will try to figure out if it has spread, and if so, how far. This process is called staging. The stage describes how much cancer is in the body. It helps determine how serious the lymphoma is and how best to treat it.
Tests used to gather information for staging can include:
In general, the results of imaging tests such as PET or CT scans are the most important when determining the stage of the lymphoma.
A staging system is a way for members of a cancer care team to sum up the extent of a cancer’s spread. The current staging system for NHL in adults is known as the Lugano classification, which is a modified version of the older Ann Arbor system.
The stages are described by Roman numerals I through IV (1-4). Limited stage (I or II) lymphomas that affect an organ outside the lymph system (an extranodal organ) have an E added (for example, stage IIE).
Either of the following means the disease is stage I:
Either of the following means the disease is stage II:
Either of the following means the disease is stage III:
The lymphoma has spread widely into at least one organ outside the lymph system, such as the bone marrow, liver, or lung.
This term is often used to describe large tumors in the chest. It is especially important for stage II lymphomas, as bulky disease might need more intensive treatment.
The system above is most often used to stage SLL if it is only in lymph nodes. But if the disease is in the blood or bone marrow, it is often staged using the systems for CLL. See Chronic Lymphocytic Leukemia Stages.
The stage of a lymphoma is important when determining a person’s treatment options, but it is more important for some types of lymphoma than for others. For many of the more common types of NHL, treatment is based in part on whether the lymphoma is “limited” (stage I or stage II non-bulky) or “advanced” (stage III or IV). For stage II bulky lymphomas, certain other factors (known as prognostic factors) are used to help determine if the lymphoma should be treated as limited or advanced.
For some other types of NHL, such as fast-growing lymphomas like Burkitt lymphoma, the stage is less important when deciding on treatment.
See Treating B-cell Non-Hodgkin Lymphomas and Treating T-cell Non-Hodgkin Lymphomas for more on this.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Almaimani J, Tsoumpas C, Feltbower R, Polycarpou I. FDG PET/CT versus bone marrow biopsy for diagnosis of bone marrow involvement in non-Hodgkin lymphoma: a systematic review. App Sci. 2022;12(2):540.
Freedman AS, Friedberg JW. Pretreatment evaluation and staging of non-Hodgkin lymphomas. UpToDate. 2023. Accessed at https://www.uptodate.com/contents/pretreatment-evaluation-and-staging-of-non-hodgkin-lymphomas on November 30, 2023.
Freedman AS, Friedberg JW, Aster JC. Clinical presentation and initial evaluation of non-Hodgkin lymphoma. UpToDate. 2023. Accessed at https://www.uptodate.com/contents/clinical-presentation-and-initial-evaluation-of-non-hodgkin-lymphoma on November 30, 2023.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: B-Cell Lymphomas. Version 6.2023. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf on November 30, 2023.
Steinbuss G, Kriegsmann M, Zgorzelski C, Brobeil A, Goeppert B, Dietrich S, Mechtersheimer G, Kriegsmann K. Deep learning for the classification of non-Hodgkin lymphoma on histopathological images. Cancers. 2021;13(10):2419. https://doi.org/10.3390/cancers13102419
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H. NCCN guidelines® insights: Chronic Lymphocytic leukemia/small Lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2022;20(6):622-34.
Last Revised: February 15, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.